120 related articles for article (PubMed ID: 38722455)
1. Investigation into in silico and in vitro approaches for inhibitors targeting MCM10 in Leishmania donovani: a comprehensive study.
Saha S; Sharma A; Bhowmik D; Kumar D
Mol Divers; 2024 May; ():. PubMed ID: 38722455
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of potential drugs against leishmaniasis targeting catalytic subunit of
Bhowmik D; Jagadeesan R; Rai P; Nandi R; Gugan K; Kumar D
J Biomol Struct Dyn; 2021 Mar; 39(5):1838-1852. PubMed ID: 32141397
[No Abstract] [Full Text] [Related]
3. In-silico studies on Myo inositol-1-phosphate synthase of
Sinha M; Jagadeesan R; Kumar N; Saha S; Kothandan G; Kumar D
J Biomol Struct Dyn; 2022 May; 40(8):3371-3384. PubMed ID: 33200690
[TBL] [Abstract][Full Text] [Related]
4. Drug repurposing based novel anti-leishmanial drug screening using
Rai P; Arya H; Saha S; Kumar D; Bhatt TK
J Biomol Struct Dyn; 2022; 40(21):10812-10820. PubMed ID: 36529188
[TBL] [Abstract][Full Text] [Related]
5. Computational evaluation of phytochemicals targeting DNA topoisomerase I in
Arya PK; Mandal P; Barik K; Singh DV; Kumar A
J Biomol Struct Dyn; 2023 Sep; ():1-14. PubMed ID: 37697722
[TBL] [Abstract][Full Text] [Related]
6. Exploration of New and Potent Lead Molecules Against CAAX Prenyl Protease I of Leishmania donovani Through Pharmacophore Based Virtual Screening Approach.
Prabhu SV; Tiwari K; Suryanarayanan V; Dubey VK; Singh SK
Comb Chem High Throughput Screen; 2017; 20(3):255-271. PubMed ID: 28116998
[TBL] [Abstract][Full Text] [Related]
7. Drug repositioning to discover novel ornithine decarboxylase inhibitors against visceral leishmaniasis.
Sheikh SY; Ansari WA; Hassan F; Faruqui T; Khan MF; Akhter Y; Khan AR; Siddiqui MA; Al-Khedhairy AA; Nasibullah M
J Mol Recognit; 2023 Jul; 36(7):e3021. PubMed ID: 37092713
[TBL] [Abstract][Full Text] [Related]
8. A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line.
Jain SK; Sahu R; Walker LA; Tekwani BL
J Vis Exp; 2012 Dec; (70):. PubMed ID: 23299097
[TBL] [Abstract][Full Text] [Related]
9. Identification of potential inhibitor against Leishmania donovani mitochondrial DNA primase through in-silico and in vitro drug repurposing approaches.
Nath M; Bhowmik D; Saha S; Nandi R; Kumar D
Sci Rep; 2024 Feb; 14(1):3246. PubMed ID: 38332162
[TBL] [Abstract][Full Text] [Related]
10. Suramin could block the activity of Arabinono-1, 4-lactone oxidase enzyme from Leishmania donovani: structure-based screening and molecular dynamics analyses.
Adinehbeigi K; Shaddel M; Khalili S; Zakeri A
Trans R Soc Trop Med Hyg; 2020 Feb; 114(3):162-172. PubMed ID: 31667504
[TBL] [Abstract][Full Text] [Related]
11. Computational multi-target approach to target essential enzymes of Leishmania donovani using comparative molecular dynamic simulations and MMPBSA analysis.
Saha D; Nath Jha A
Phytochem Anal; 2023 Oct; 34(7):842-854. PubMed ID: 36760044
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of New Cyclic Imides Derived from Safrole, Structure- and Ligand-based Approaches to Evaluate Potential New Multitarget Agents Against Species of Leishmania.
de Sousa Luis JA; da Silva Costa NA; Luis CCS; Lira BF; Athayde-Filho PF; de Souza Lima TK; da Câmara Rocha J; Scotti L; Scotti MT
Med Chem; 2020; 16(1):39-51. PubMed ID: 31208311
[TBL] [Abstract][Full Text] [Related]
13. Structure-based virtual screening, molecular docking, ADMET and molecular simulations to develop benzoxaborole analogs as potential inhibitor against Leishmania donovani trypanothione reductase.
Pandey RK; Kumbhar BV; Sundar S; Kunwar A; Prajapati VK
J Recept Signal Transduct Res; 2017 Feb; 37(1):60-70. PubMed ID: 27147242
[TBL] [Abstract][Full Text] [Related]
14. Dual-target drugs against Leishmania donovani for potential novel therapeutics.
Bora K; Sarma M; Kanaujia SP; Dubey VK
Sci Rep; 2023 Oct; 13(1):18363. PubMed ID: 37884555
[TBL] [Abstract][Full Text] [Related]
15. Screening of Novel Inhibitors Against Leishmania donovani Calcium ion Channel to Fight Leishmaniasis.
Kashif M; Manna PP; Akhter Y; Alaidarous M; Rub A
Infect Disord Drug Targets; 2017; 17(2):120-129. PubMed ID: 28034363
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of antileishmanial potential of computationally screened compounds targeting DEAD-box RNA helicase of Leishmania donovani.
Pandey SC; Jha A; Kumar A; Samant M
Int J Biol Macromol; 2019 Jan; 121():480-487. PubMed ID: 30321635
[TBL] [Abstract][Full Text] [Related]
17. Natural products derived steroids as potential anti-leishmanial agents; disease prevalence, underlying mechanisms and future perspectives.
Elawad MA; Elkhalifa MEM; Hamdoon AAE; Salim LHM; Ahmad Z; Ayaz M
Steroids; 2023 May; 193():109196. PubMed ID: 36764565
[TBL] [Abstract][Full Text] [Related]
18. Developing imidazole analogues as potential inhibitor for Leishmania donovani trypanothione reductase: virtual screening, molecular docking, dynamics and ADMET approach.
Pandey RK; Sharma D; Bhatt TK; Sundar S; Prajapati VK
J Biomol Struct Dyn; 2015; 33(12):2541-53. PubMed ID: 26305585
[TBL] [Abstract][Full Text] [Related]
19. A Molecular Modeling Approach to Identify Potential Antileishmanial Compounds Against the Cell Division Cycle (cdc)-2-Related Kinase 12 (CRK12) Receptor of
Broni E; Kwofie SK; Asiedu SO; Miller WA; Wilson MD
Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33803906
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the inhibitory potential of Valproic acid against histone deacetylase of
Prasanna P; Joshi T; Pant M; Pundir H; Chandra S
J Biomol Struct Dyn; 2023; 41(12):5447-5464. PubMed ID: 35706132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
